Minapharm Pharmaceuticals S.A.E. specializes in developing, manufacturing and marketing prescription pharmaceutical products. The products are for the treatment of gastroenterological, ophthalmologic, cardiovascular, genetic, dermatological, orthopedic diseases, etc.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
22/10/26	EGP 742.36	-0.77%	578
21/10/26	EGP 748.10	-0.43%	6,731
20/10/26	EGP 751.34	-0.59%	2,516
19/10/26	EGP 755.83	+0.78%	2,678
18/10/26	EGP 750.00	-5.48%	33,486

End-of-day quote Egyptian Exchange

More quotes

End-of-day quote Egyptian Exchange 22/10/2026			5-day change	1st Jan Change
742.36 ^EGP	-0.77%		-6.44%	+112.59%

10-04	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-27	CEPI backs Minapharm's experimental Ebola vaccine with up to $16.5 million funding	RE

Market Cap	8.75B 158M 141M 130M 118M 221M 15.01B 225M 1.57B 622M 7.87B 594M 581M 24.8B	P/E 2024	14x	P/E 2025	584x
Enterprise Value	9.86B 178M 159M 147M 133M 249M 16.92B 253M 1.77B 700M 8.86B 669M 655M 27.95B	EV / Sales 2024	0.78x	EV / Sales 2025	0.81x
Free-Float	15.13%	Yield 2024	1.54%	Yield 2025	-

10-04	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-27	CEPI backs Minapharm's experimental Ebola vaccine with up to $16.5 million funding	RE
08-27	Minapharm Group Receives Funding to Advance Bundibugyo Ebolavirus Vaccine Candidate to Clinical Trials	CI
08-17	MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
06-10	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-05	Minapharm pharmaceuticals FY standalone net profit EGP 57.5 million	RE
11-30	Minapharm Pharmaceuticals Q3 consol profit egp 16.8 million	RE
11-29	MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/09/25	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
14/09/25	Minapharm Pharmaceuticals Q2 consol profit EGP 40 million	RE
27/07/25	MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
27/07/25	Minapharm Pharmaceuticals Q1 consol net loss EGP 2 million	RE
12/06/25	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2024	CI

07/07/25	EBRD, Admaius Capital plan to acquire 15%-20% of Egyptian Minapharm Pharmaceuticals	AQ
26/03/25	African Development Bank Approves Eur 15 Million Loan to Boost Biosimilars' Development and Production in Egypt	AQ
05/10/23	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries	AQ
04/10/23	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia	AQ
06/03/23	Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa	AQ

MINAPHARM Pharmaceuticals Share Price

Stocks

MIPH

EGS380G1C011

Pharmaceuticals

Valuation: MINAPHARM Pharmaceuticals

Chart: MINAPHARM Pharmaceuticals

Latest news: MINAPHARM Pharmaceuticals

Press Releases: MINAPHARM Pharmaceuticals

Quotes and Performance

Price Extremes

Managers and Directors: MINAPHARM Pharmaceuticals

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 day	-0.77%
1 week	-6.44%
Current month	-4.79%
1 month	-15.64%
3 months	-0.58%
6 months	+31.94%
Current year	+112.59%

1 week	686.2	798
1 month	666.66	879
Current year	320.23	1,000
1 year	302.22	1,000
3 years	145	1,000
5 years	101.05	1,000
10 years	45	1,000

Manager	Title	Age	Since
Shaheer Wafeeq Sa'ad Al-Bardissy CEO	Chief Executive Officer	-	-
Wafik El-Bardissy CEO	Chief Executive Officer	-	18/10/2010
Rafiq Raymond DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Wafik El-Bardissy CHM	Chairman	-	17/10/2010
Anwar Nasr Mekhaeel BRD	Director/Board Member	-	17/10/2010
Amr Mohamed Sobhi Hamza El-Shabrawishy BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MINAPHARM PHARMACEUTICALS	-0.77%	-6.44%	+127.59%	+263.94%	158M
ELI LILLY AND COMPANY	-2.91%	+1.01%	+54.66%	+120.20%	1,165B
JOHNSON & JOHNSON	-1.57%	+3.08%	+36.87%	+74.01%	645B
ABBVIE INC.	+0.38%	+0.30%	+25.42%	+97.79%	504B
ROCHE HOLDING AG	-0.31%	+3.09%	+43.92%	+64.55%	380B
MERCK & CO., INC.	-1.69%	-0.71%	+66.22%	+40.21%	363B
NOVARTIS AG	-0.68%	+2.65%	+22.46%	+51.48%	297B
ASTRAZENECA PLC	-1.20%	+3.04%	+2.62%	+26.97%	269B
AMGEN INC.	-1.39%	+2.01%	+50.63%	+61.57%	237B
GILEAD SCIENCES, INC.	-0.11%	+0.56%	+30.09%	+102.51%	195B
Average	-1.04%	+2.19%	+46.05%	+90.32%	405.56B
Weighted average by Cap.	-1.44%	+3.17%	+41.00%	+82.19%

	2024	2025
Net sales	5.66B 102M 91.48M 84.51M 76.58M 143M 9.72B 146M 1.02B 403M 5.09B 384M 376M 16.06B	6.44B 116M 104M 96.04M 87.04M 163M 11.05B 166M 1.16B 458M 5.79B 437M 428M 18.26B
Net income	157M 2.84M 2.54M 2.34M 2.12M 3.97M 270M 4.04M 28.2M 11.16M 141M 10.66M 10.43M 445M	40.22M 727K 649K 600K 544K 1.02M 69.04M 1.03M 7.22M 2.86M 36.17M 2.73M 2.67M 114M
Net Debt	2.6B 46.98M 41.96M 38.76M 35.12M 65.71M 4.46B 66.8M 466M 185M 2.34B 176M 173M 7.37B	1.11B 20.07M 17.93M 16.56M 15.01M 28.08M 1.91B 28.54M 199M 78.9M 998M 75.34M 73.74M 3.15B